GlassScriptPhysician profile
Danielle S Forte
NPI 1780972810
$7,423.99
in general payments reported to CMS, 2019-2025
31 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $989 · 2022: $1,660 · 2023: $2,087 · 2024: $1,220 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,675 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,674.58 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,086.05 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $1,046.13 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $846.05 | 2021-2024 | |
| Glaxosmithkline, LLC. | $838.87 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $725.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $517.69 | 2021-2025 | |
| Astellas Pharma US INC | $318.39 | 2021-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.11 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $262.76 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.25 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $229.20 | 2022 | |
| Exact Sciences Corporation | $179.52 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Shield Therapeutics INC | $151.55 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $66.83 | 2022-2023 | Quviviq |
| Antares Pharma, INC. | $65.62 | 2022-2023 | Tlando, Xyosted, Nocdurna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $64.05 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $60.56 | 2021-2023 | Freestyle Libre 2 |
| Dexcom, INC. | $54.17 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $53.25 | 2025 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $51.39 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $49.02 | 2023 | |
| Amarin Pharma, INC. | $40.28 | 2021-2022 | |
| Avvisto Therapeutics, LLC | $34.16 | 2025 | Cycloset |
| Avion Pharmaceuticals | $26.46 | 2022 | |
| Merck Sharp & Dohme LLC | $21.60 | 2021 | |
| Recordati_rare_diseases_inc. | $18.90 | 2023 | Cystadrops |
| Biohaven Pharmaceuticals, INC. | $18.46 | 2021 | |
| Ibsa Pharma INC. | $16.66 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.09 | 2021 | |
| Sumitomo Pharma America, INC. | $14.63 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Forte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.